Amicus Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03152W1099
USD
14.27
8.24 (136.65%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Amicus Therapeutics, Inc. stock-summary
stock-summary
Amicus Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
Company Coordinates stock-summary
Company Details
1 Cedarbrook Dr , CRANBURY NJ : 08512-3618
stock-summary
Tel: 1 609 6622000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 64 Schemes (39.47%)

Foreign Institutions

Held by 141 Foreign Institutions (16.73%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. John Crowley
Chairman of the Board and Chief Executive Officer
Mr. Bradley Campbell
President, Chief Operating Officer, Director
Mr. Michael Raab
Lead Independent Director
Ms. Lynn Bleil
Independent Director
Mr. Robert Essner
Independent Director
Mr. Michael Kelly
Independent Director
Ms. Margaret McGlynn
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
169 Million
(Quarterly Results - Sep 2025)
Net Profit:
17 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4,439 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.59

stock-summary
Return on Equity

-5.36%

stock-summary
Price to Book

19.26